Epizyme (NASDAQ:EPZM) announced its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.05, Bloomberg Earnings reports. Epizyme’s quarterly revenue was down 100.0% compared to the same quarter last year.
Epizyme stock opened at $14.85 on Friday. The stock has a market capitalization of $1,194.37, a PE ratio of -6.81 and a beta of 1.96. Epizyme has a 52 week low of $9.30 and a 52 week high of $21.40.
A number of analysts have weighed in on EPZM shares. Oppenheimer set a $26.00 price target on Epizyme and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Cann reaffirmed a “buy” rating and issued a $26.00 price target on shares of Epizyme in a research report on Tuesday, December 12th. Jefferies Group reaffirmed a “buy” rating and issued a $25.00 price target on shares of Epizyme in a research report on Wednesday, January 24th. Roth Capital started coverage on Epizyme in a research report on Thursday, February 1st. They issued a “buy” rating and a $24.00 price target for the company. Finally, BidaskClub upgraded Epizyme from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $23.50.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. MetLife Investment Advisors LLC bought a new position in Epizyme during the fourth quarter valued at about $263,000. Palo Alto Investors LLC increased its stake in Epizyme by 7.2% during the fourth quarter. Palo Alto Investors LLC now owns 6,860,843 shares of the biopharmaceutical company’s stock valued at $86,104,000 after acquiring an additional 462,547 shares during the period. Redmile Group LLC increased its stake in Epizyme by 59.1% during the fourth quarter. Redmile Group LLC now owns 1,925,689 shares of the biopharmaceutical company’s stock valued at $24,167,000 after acquiring an additional 715,689 shares during the period. Macquarie Group Ltd. increased its stake in Epizyme by 100.7% during the fourth quarter. Macquarie Group Ltd. now owns 82,485 shares of the biopharmaceutical company’s stock valued at $1,035,000 after acquiring an additional 41,385 shares during the period. Finally, Millennium Management LLC increased its stake in Epizyme by 56.4% during the fourth quarter. Millennium Management LLC now owns 996,687 shares of the biopharmaceutical company’s stock valued at $12,508,000 after acquiring an additional 359,547 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by BBNS and is the property of of BBNS. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://baseballnewssource.com/2018/04/07/epizyme-epzm-posts-earnings-results-beats-estimates-by-0-05-eps/2038193.html.
Epizyme Company Profile
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.